Life Science Company News

Silence Therapeutics to Participate in Fireside Chat at the RBC Capital Markets Global Healthcare Conference

Silence Therapeutics to Participate in Fireside Chat at the RBC Capital Markets Global Healthcare Conference

12 May 2021

LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced the Company will participate in a fireside chat at the virtual RBC Capital Markets Global Healthcare Conference on Wednesday, May 19th at 8:35 a.m. ET / 1:35 p.m. BST

A live webcast of the presentation can be accessed via the Investors section of Silence’s website at www.silence-therapeutics.com. An archived replay of the webcast will be available on the Company's website following the conference.

Enquiries:

Silence Therapeutics plc

Gem Hopkins, Head of IR and Corporate Communications

ir@silence-therapeutics.com



Tel:  +1 (646) 637-3208
   Investec Bank plc (Nominated Adviser and Broker)

Daniel Adams/Gary Clarence

 
Tel:  +44 (0) 20 7597 5970
European PR

Consilium Strategic Communications

Mary-Jane Elliott/ Angela Gray / Chris Welsh

silencetherapeutics@consilium-comms.com

 
Tel: +44 (0) 20 3709 5700

About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron loading anemias. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Takeda, among others. For more information, please visit https://www.silence-therapeutics.com/.


By: GlobenewsWire - 12 May 2021
Back to overview

Enhance your business development with Biotechgate